Vertex Pharmaceuticals Incorporated took another important step in its efforts to develop a NaV1.8 inhibitor for chronic pain on 13 December, reporting that VX-548 demonstrated statistical significance at three doses in diabetic peripheral neuropathy (DPN) versus a reference arm of Pfizer Inc.’s Lyrica (pregabalin). Analysts noted that while the drug hit the efficacy bar in DPN with data numerically similar to Lyrica, its best hope to compete in the generic-dominated pain market may lie in showing a better safety and tolerability profile.
Key Takeaways
-
Vertex’s VX-548 demonstrated efficacy for chronic pain reduction in a Phase II study in diabetic peripheral neuropathy.
-
The drug is a key component of Vertex’s efforts to develop non-opioid pain therapies for both acute and chronic pain indications
In a 192-patient, Phase II dose-ranging study, 23mg, 46mg and 69mg daily doses of VX-548 met statistical significance and showed what Vertex called clinically meaningful benefit in reducing pain 12 weeks from baseline as measured by the Numeric Pain Rating Scale
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
